“… 22 In fact, one of the strongest arguments for the use of MMS in LM/LMM in particular is the issue of subclinical spread. 3 , 8 , 10 , 13 , 16 , 18 , 24 , 25 , 28 , 37 , 50 Subclinical spread occurs in 12%–71% of LM cases and refers to the microscopic extension of the tumor beyond the clinically apparent borders. 24 , 26 , 50 , 51 …”